SCHEMBL18506544

SCHEMBL18506544

CC(=O)O[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(=O)CO)[C@@H]2CCC3=CC(=O)CC[C@]3(C)[C@H]21

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C2 P08235 8/20 0.68
PGR P06401 4/20 0.66
NR3C1 P04150 3/20 0.66
HIF1A Q16665 7/20 0.65
KMT2A Q03164 2/20 0.65
CYP3A4 P08684 3/20 0.62
ALDH1A1 P00352 1/20 0.62
AR P10275 3/20 0.60
CHRM1 P11229 2/20 0.59
HSD17B10 Q99714 4/20 0.57
CYP2C19 P33261 3/20 0.57
SERPINA6 P08185 3/20 0.57
SHBG P04278 2/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
MAPT P10636 1/20 0.57
NFKB1 P19838 1/20 0.57
LMNA P02545 3/20 0.53
BLM P54132 1/20 0.52
PMP22 Q01453 1/20 0.52
TSHR P16473 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11525870 0.91 AR (0.71) NR3C2PGRNR3C1HIF1AKMT2A
SCHEMBL11525865 0.91 AR (0.71) NR3C2PGRNR3C1HIF1AKMT2A
SCHEMBL3049344 0.89 NR3C2 (0.84) NR3C2PGRNR3C1HIF1AKMT2A
SCHEMBL321463 0.89 NR3C2 (0.84) NR3C2PGRNR3C1HIF1AKMT2A
SCHEMBL18506541 0.89 AR (0.64) NR3C2PGRNR3C1HIF1AKMT2A
SCHEMBL18506540 0.89 PGR (0.60) NR3C2PGRNR3C1HIF1AKMT2A
SCHEMBL20553192 0.89 NR3C2 (0.82) NR3C2PGRNR3C1HIF1AKMT2A
SCHEMBL23456329 0.86 NR3C2 (0.70) NR3C2PGRNR3C1HIF1AKMT2A
SCHEMBL122186 0.85 NR3C2 (0.79) NR3C2PGRNR3C1HIF1AKMT2A
SCHEMBL6565022 0.84 AR (0.82) NR3C2PGRNR3C1HIF1AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200339983-A1 BIOACTIVE CONJUGATES FOR OLIGONUCLEOTIDE DELIVERY UNIVERSITY OF MASSACHUSETTS 2020-10-29 US disclosed
US-20190185855-A1 CONJUGATED OLIGONUCLEOTIDES UNIVERSITY OF MASSACHUSETTS 2019-06-20 US disclosed
US-20170043024-A1 BIOACTIVE CONJUGATES FOR OLIGONUCLEOTIDE DELIVERY UNIVERSITY OF MASSACHUSETTS 2017-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200339983-A1 BIOACTIVE CONJUGATES FOR OLIGONUCLEOTIDE DELIVERY DCLRE1B, RTCB, RNASE1 NR3C2 3351/4885PGR 3592/4885NR3C1 2841/4885
US-20170043024-A1 BIOACTIVE CONJUGATES FOR OLIGONUCLEOTIDE DELIVERY DCLRE1B, RTCB, RNASE1 NR3C2 3351/4885PGR 3592/4885NR3C1 2841/4885
US-20190185855-A1 CONJUGATED OLIGONUCLEOTIDES DCLRE1B, DCLRE1A, TNNC1 NR3C2 1917/4885PGR 2957/4885NR3C1 1384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.